Summit Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Jul 23, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 23, 2026
SMMT$17.83-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development (1) | $157,733 | $208,021 | $290,351 | $259,286 |
| General and administrative | 62,763 | 360,416 | 125,357 | 376,002 |
| Total operating expenses | 220,496 | 568,437 | 415,708 | 635,288 |
| Other income, net | 4,796 | 2,729 | 10,584 | 6,667 |
| Net loss | $(215,700) | $(565,708) | $(405,124) | $(628,621) |
| Net loss per share: | ||||
| Basic and diluted | $(0.28) | $(0.76) | $(0.52) | $(0.85) |
| Weighted average common shares outstanding: | ||||
| Basic and diluted | 778,184,568 | 742,615,007 | 776,824,812 | 740,358,044 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation adjustments | 34 | (189) | 118 | (334) |
| Unrealized loss on short-term investments | (67) | — | (243) | (133) |
| Comprehensive loss | $(215,733) | $(565,897) | $(405,249) | $(629,088) |
(1) Refer to Note 11 – Related Party Transactions for expenses incurred.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.